Alinia C, Yaghmaei S, Abdullah FZ, et al. - Given the correlation of COVID-19 with a high mortality rate and a significant reduction in the patient’s Health-Related Quality of Life (HRQoL), researchers aimed to measure this effect. They herein conducted a cross-sectional study in Iran including 320 randomly selected treated patients from COVID-19 and estimated the health utility value and its clinical and socio-demographic determinants among these patients. They obtained the overall mean (median) of the disease as 0.863 (0.909), which means that an average of 13.7% of the HRQoL is lost among patients who suffered from COVID-19. However, on excluding non-traders from the analysis, there will be a significant reduction in the mean (median) of the disease utility by 0.793 (0.848). In other words, an average of 20.7% of the HRQoL is lost among people who are severely affected by the disease. Overall observations suggest a substantial burden of disease caused by COVID-19. The lowest utility value was recorded for patients with underlying disease, hospitalized in the ICU, or those with severe lung involvement when compared with other patients with the disease, losing nearly 18%–33% of their HRQoL. In addition, the participants’ age and hospitalization status were identified to be the key determinants of COVID-19 health utility value in the regression analysis.